Article Text

Download PDFPDF

Sicca: an important manifestation of damage in systemic sclerosis (SSc) and SSc-overlap syndromes. Response to ‘Do the salivary glands of patients with systemic sclerosis show ultrasonographic modifications suggestive of Sjögren's syndrome?’ by Coudrec et al
  1. Mandana Nikpour
  1. Department of Medicine, University of Melbourne, Fitzroy, VIC 3065, Australia
  1. Correspondence to Dr Mandana Nikpour, Department of Medicine, University of Melbourne, Fitzroy, VIC 3065, Australia; m.nikpour{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We thank Dr Couderc et al for reporting this interesting study of ultrasonographic changes in salivary glands of patients with systemic sclerosis (SSc).1 Their findings of a high frequency of xerostomia and xerophthalmia, together with morphological echostructure modifications of the major salivary glands in patients with SSc, support the inclusion of sicca symptoms as an item in the Scleroderma Clinical Trials Consortium-Damage Index (SCTC-DI).2 As pointed out by Dr Couderc et al, sicca symptoms feature prominently in the SCTC-DI, being assigned 3 points of a total possible score of 55. This weighting reflects the strong association of sicca symptoms with the SF-36 quality of life score, a surrogate measure of morbidity used along with mortality data to weight the SCTC-DI items. Collectively, the inclusion of sicca symptoms in the SCTC-DI and the findings reported in this French study underpin the importance of sicca symptoms as a key manifestation of SSc and SSc-overlap syndromes, which is greatly in need of further research and effective therapies.



  • Handling editor Josef S Smolen

  • Funding The author has not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles